Interestinghttps://www.bloomberg.com/news/articles/2022-01-30/flight-from-risk-drives-biotech-stocks-to-worst-start-since-2016?
Article dated: Jan 30, 2022.
Stocks from just about every corner of the health-care industry have been beaten back this month as investors retreat from risk. But few have been hit as hard as biotechnology.
Still, there may be signs that the biotech downturn is reaching its nadir. The equal-weighted SPDR S&P Biotech ETF, which trades under the ticker XBI, plunged 50% over seven months during the Clinton-fueled rout before its next advance. It has experienced a similar-sized drop over the past year, suggesting it could be primed for a reversal.
But Jefferies analysts said the current selloff is lasting longer than past ones -- and that may mean it will take more time for investors to regain their confidence.
Take away: Aligns pretty much with the LXG.V trajectory of late.